Founded in 2020, Capital Pulse revolutionizes healthcare finance by converting stagnant medical receivables into immediate liquidity. Led by experts in data science and finance, we use our AI-powered CP Engine to predict coding errors and denials before they happen. Unlike traditional factoring, we partner with banks to provide low-cost working capital. We empower providers to move from defensive cash hoarding to strategic growth, ensuring financial stability and better patient care.
BTBC Oncologic
BTBC Oncologic, Inc. develops OncoSol Prime™, a governed AI host‑modulation system that builds a “medical digital clone” for each patient. By forecasting health risks and generating personalized protocols, it reduces toxicity and hospitalizations—saving payers money. Our validated platform also serves as a reimbursable clinical decision‑support tool and a clinical trial endpoint. We are ready for clinical deployment and strategic partnerships.
Brandon Systems
About Brandon Systems For over two decades, Brandon Systems has helped healthcare organizations modernize systems and unlock value from siloed data. As healthcare evolved toward data-driven intelligence, we partnered with Microsoft to build on Microsoft Fabric—a unified platform that simplifies data architecture and accelerates insights. We then created FabricExpress™, empowering providers and payors to turn data into actionable intelligence. | For over two decades, Brandon Systems has helped healthcare organizations modernize systems and unlock value from siloed data. As healthcare evolved toward data-driven intelligence, we partnered with Microsoft to build on Microsoft Fabric—a unified platform that simplifies data architecture and accelerates insights. We then created FabricExpress™, empowering providers and payors to turn data into actionable intelligence.
BioAro
BioAro Inc. is a leading biotechnology company specializing in whole genome sequencing and advanced genetic analysis. With a strong commitment to personalized medicine, BioAro leverages cutting-edge genomic technologies to provide individuals, healthcare professionals, and researchers with comprehensive insights into genetic health, disease predisposition, and personalized wellness strategies. At the core of BioAro’s services is its whole genome sequencing platform, which delivers high-precision genetic data that empowers users to make informed health decisions. The company’s offerings extend beyond raw data by providing advanced interpretation through proprietary bioinformatics pipelines and AI-driven analytics. By transforming complex genetic information into actionable insights, BioAro enables early disease detection, risk assessment, and tailored treatment recommendations. BioAro is dedicated to bridging the gap between genomic science and real-world application by making genetic testing accessible and understandable. Its services cater to a diverse clientele, including individuals interested in proactive health management, clinicians seeking precision medicine solutions, and researchers aiming to advance genetic discoveries. The company also collaborates with pharmaceutical and healthcare organizations to support drug development and personalized therapeutics. With a focus on innovation and data security, BioAro upholds the highest standards of accuracy and confidentiality. Its state-of-the-art sequencing facilities adhere to rigorous quality controls, ensuring reliable results that users can trust. As the demand for personalized medicine grows, BioAro continues to expand its capabilities, staying at the forefront of genomic advancements to improve health outcomes and revolutionize the future of healthcare. | BioAro Inc., established in 2021, is a Canadian biotechnology company headquartered in Calgary, Alberta. The company specializes in precision health, health span, and longevity, integrating genomics, artificial intelligence (AI), and blockchain technologies to deliver personalized healthcare solutions. BioAro’s mission is to revolutionize personalized healthcare through its cutting-edge technologies, including the BioPhenome Lab, BioHealth software solutions, Biospan clinics, and biotech devices. The company’s vision focuses on extending human healthspan by integrating innovative approaches for a healthier future. BioAro operates internationally, with Headoffice in Calgary, Canada; and offices in Dubai, United Arab Emirates; and Almelo, The Netherlands, and United Kingdom reflecting its commitment to making personalized medicine accessible worldwide. BioAro aims to transform healthcare from reactive disease management to proactive health optimization, empowering individuals to take control of their health and well-being. | BioAro Inc. is a Calgary-based precision health biotechnology company advancing real-time, AI-driven multi-omics solutions for personalized medicine. Its PanOmiQ™ platform integrates genomic, epigenomic, pharmacogenomic, microbiome, and clinical data to deliver rapid, scalable insights that support early disease detection, tailored treatment strategies, and predictive healthcare. BioAro’s ecosystem improves clinical decision-making and expands precision medicine markets.
AVTRMed, Inc.
AVTRMed is building Nora, an AI clinic assistant purpose-built for ophthalmology and optometry practices. Founded by practicing optometrist with a management team bringing decades of eye care, Nora combines voice AI and conversational agents to automate administrative and business operations across eye care workflows. Using proprietary multi-agent architecture, Nora delivers human-like patient interactions while reducing staff burden and operational costs.
Avarion
Avarion (formerly Huntzinger) delivers strategic clarity, operational excellence, and measurable results to healthcare organizations nationwide. Backed by decades of real-world experience, our team of former healthcare executives, clinicians, and technologists brings unmatched insight into the complexities of today’s healthcare environment—because we’ve led it from the inside. From shaping the modern HIT landscape to executing solutions that reduce risk, optimize performance, and accelerate ROI.